MedBen Rx Blog

Getting Down to the (MedBen) Basics

Health benefits management can be a complicated business, but that doesn’t mean it has to be. To help make things a bit more clear cut, MedBen offers dozens of MedBen Basic handouts on a variety of topics. While many of our Basics are directed at plan...

read more

Drugmakers (Kind of) Lower Insulin Costs

Earlier this month, drug manufacturer Eli Lilly announced that it cutting the cost of two of its prescription brand insulins, Humalog and Humulin, by 70%, and capping out-of-pocket costs for privately insured patients at $35 a month. Competing...

read more

Comparative Effectiveness Silences the Drug Ad Hype

Drug companies spend $6 billion per year on direct-to-consumer ads with the goal of getting patients to ask their doctors to prescribe drugs that, in many instances, cost substantially more but are less effective than their current medications. And with no comparative...

read more

The 2023 MedBen University Season Starts Soon!

The 22nd Season of MedBen University (MBU) will soon be in session! In 2023, MBU will explore current benefit management issues and proven solutions MedBen offers, including: golden pen,notebook,calculator and glasses on black desk Reducing Rx spend...

read more

PBMs, GoodRx on the Legislative Hot Seat

Pharmacy benefits managers (PBMs) are increasingly being called to answer for their questionable business practices at multiple levels of government. On the state level, in recent months: A major PBM has settled with Iowa and at least 14 other states for...

read more

How Do Health Plans Manage High-Cost Drug Spend?

In two recent articles, we touched on the growing prevalence of high-cost drugs, some with price tags in the thousands and even millions of dollars: Drugmakers are raising prices on over 350 unique drugs this month.Innovative gene therapies have emerged that cost as...

read more

Drugmakers Raising Prices on Over 350 Drugs in January

From Reuters: "Drugmakers including Pfizer Inc, GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3...

read more

MedBen Rx Has Solutions for Rising Specialty Drug Costs

From earlier this year: “Health plans and pharmacy benefit managers (PBMs) that manage drug costs… say specialty drugs now account for 50% or greater of the total prescription spending they manage. In some cases, employer clients are seeing specialty costs account...

read more

Gene Therapy: Big Benefits at a Big Cost

The Self-Insurer magazine recently examined the emergence of innovative gene therapies that carry substantial benefits… and hefty price tags. The FDA just approved a hemophilia B gene therapy that costs $3.5 million a dose, making it the...

read more